Conference scene: Immune signatures in the tumor and beyond.


Autoria(s): Kandalaft L.E.; Kalos M.; Melief C.J.; Speiser D.E.; Coukos G.
Data(s)

2012

Resumo

Led by key opinion leaders in the field, the Cancer Immunotherapy Consortium of the Cancer Research Institute 2012 Scientific Colloquium included 179 participants who exchanged cutting-edge information on basic, clinical and translational cancer immunology and immunotherapy. The meeting revealed how rapidly this field is advancing. The keynote talk was given by Wolf H Fridman and it described the microenvironment of primary and metastatic human tumors. Participants interacted through oral presentations and panel discussions on topics that included host reactions in tumors, advances in imaging, monitoring therapeutic immune modulation, the benefit and risk of immunotherapy, and immune monitoring activities. In summary, the annual meeting gathered clinicians and scientists from academia, industry and regulatory agencies from around the globe to interact and exchange important scientific advances related to tumor immunobiology and cancer immunotherapy.

Identificador

https://serval.unil.ch/?id=serval:BIB_0447F37D562A

isbn:1750-7448 (Electronic)

pmid:22947003

doi:10.2217/imt.12.70

isiid:000307915800007

Idioma(s)

en

Fonte

Immunotherapy, vol. 4, no. 8, pp. 761-772

Tipo

info:eu-repo/semantics/article

article